Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Xin Jin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6461-6005; OpenAlex author ID A5070066511. Sources: OpenAlex.

Their work

Papers
37 (first author 2, last author 10)
Trials
0
Grants
0
Labs led
2
Collaborators
50
Papers, trials and grants by year

2017: 3 papers · 2018: 4 papers · 2019: 5 papers · 2020: 10 papers · 2021: 6 papers · 2022: 6 papers · 2023: 2 papers · 2024: 1 paper

Papers 37

  1. ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression. Last author DOI 10.1038/s41467-024-49105-3↗
  2. MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression. First author DOI 10.15252/embj.2023114558↗
  3. Correction for: Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pan… Co-author DOI 10.18632/aging.205456↗
  4. USP22-mediated deubiquitination of PTEN inhibits pancreatic cancer progression by inducing p21 expression. Last author DOI 10.1002/1878-0261.13137↗
  5. Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors. Last author DOI 10.1002/1878-0261.13149↗
  6. FGD3 binds with HSF4 to suppress p65 expression and inhibit pancreatic cancer progression. Last author DOI 10.1038/s41388-021-02140-6↗
  7. Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor β pathway in pancreatic cancer via the TFCP2-SMAD2 axis. Co-author DOI 10.1186/s13046-022-02286-5↗
  8. CBX3 Regulated By YBX1 Promotes Smoking-induced Pancreatic Cancer Progression via Inhibiting SMURF2 Expression. Co-author DOI 10.7150/ijbs.68995↗
  9. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. First author DOI 10.7150/thno.69444↗
  10. MIB1 upregulates IQGAP1 and promotes pancreatic cancer progression by inducing ST7 degradation. Co-author DOI 10.1002/1878-0261.12955↗
  11. TRIM15 promotes the invasion and metastasis of pancreatic cancer cells by mediating APOA1 ubiquitination and degradation. Co-author DOI 10.1016/j.bbadis.2021.166213↗
  12. SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis. Co-author DOI 10.1016/j.canlet.2021.07.035↗
  13. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer. Co-author DOI 10.1038/s41419-021-04118-4↗
  14. NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15. Co-author DOI 10.1038/s41420-021-00462-8↗
  15. Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer. Co-author DOI 10.1186/s13046-021-01879-w↗
  16. GNG12 regulates PD-L1 expression by activating NF-κB signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/2211-5463.12784↗
  17. FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jcb.29468↗
  18. The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biocel.2020.105859↗
  19. The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients. Co-author DOI 10.1016/j.omto.2020.04.011↗
  20. The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis. Co-author DOI 10.1186/s12935-020-01558-4↗
  21. Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocar… Co-author DOI 10.18632/aging.102931↗
  22. MIB1 Upregulates IQGAP1 and Promotes Pancreatic Cancer Progression by inducing ST7 Degradation Co-author DOI 10.21203/rs.3.rs-76668/v1↗
  23. The aberrant expression of ADAR1 promotes resistance to BET inhibitors in pancreatic cancer by stabilizing c-Myc. Co-author PMID 32064158↗
  24. FBP1 binds to the bromodomain of BRD4 to inhibit pancreatic cancer progression. Last author PMID 32195024↗
  25. Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer. Co-author PMID 33042621↗
  26. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biocel.2019.01.011↗
  27. HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer. Last author DOI 10.1016/j.pan.2019.01.011↗
  28. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. Last author DOI 10.1186/s13046-019-1044-z↗
  29. PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer. Co-author DOI 10.1186/s13046-019-1466-7↗
  30. USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1. Last author PMID 31497353↗
  31. Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1. Last author DOI 10.1016/j.bbrc.2018.10.009↗
  32. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-018-0888-y↗
  33. Upregulation of pyruvate kinase M2 expression by fatty acid synthase contributes to gemcitabine resistance in pancreatic cancer. Last author DOI 10.3892/ol.2017.7598↗
  34. 3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer. Co-author DOI 10.3892/ol.2018.8367↗
  35. CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion. Co-author DOI 10.1074/jbc.m116.764407↗
  36. Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction. Co-author DOI 10.1158/0008-5472.can-16-3143↗
  37. Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-κB signaling pathway. Co-author DOI 10.1186/s12943-017-0627-6↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 24 shared papers, 2017–2023 · strength 3.31
  2. Dianyun Ren · 14 shared papers, 2020–2023 · strength 2.17
  3. Jingyuan Zhao · 11 shared papers, 2018–2023 · strength 1.39
  4. Ping Fan · 13 shared papers, 2017–2021 · strength 1.35
  5. Feng Guo · 6 shared papers, 2021–2023 · strength 1.09
  6. Zibo Meng · 7 shared papers, 2019–2023 · strength 0.90
  7. Chong Yang · 7 shared papers, 2017–2021 · strength 0.75
  8. Xiang Chao Cheng · 4 shared papers, 2020–2022 · strength 0.74
  9. Yingke Zhou · 5 shared papers, 2021–2022 · strength 0.73
  10. Yan Sun · 5 shared papers, 2020–2022 · strength 0.69
  11. Shikai Zhu · 5 shared papers, 2018–2022 · strength 0.58
  12. Tao Liu · 5 shared papers, 2017–2021 · strength 0.56
  13. Kun Zhang · 3 shared papers, 2020–2023 · strength 0.50
  14. Taoyu Chen · 2 shared papers, 2022–2023 · strength 0.33
  15. Bin Zhang · 2 shared papers, 2020 · strength 0.32
  16. Bin Zhang · 2 shared papers, 2020–2021 · strength 0.32
  17. Huan Zhang · 2 shared papers, 2020–2022 · strength 0.31
  18. Haixin Yu · 2 shared papers, 2022 · strength 0.29
  19. Rui Fang · 2 shared papers, 2019–2020 · strength 0.25
  20. Gengdu Qin · 2 shared papers, 2020–2022 · strength 0.25
  21. Yan Ping Sun · 2 shared papers, 2020–2021 · strength 0.25
  22. Huan Zhang · 1 shared paper, 2024 · strength 0.24
  23. Zhiqiang Liu · 2 shared papers, 2019–2021 · strength 0.24
  24. Dan Li · 1 shared paper, 2022 · strength 0.20
  25. Junpeng Meng · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.